Please use this identifier to cite or link to this item: https://scholarhub.balamand.edu.lb/handle/uob/1758
DC FieldValueLanguage
dc.contributor.authorStanford, Johnen_US
dc.contributor.authorStanford, Cynthiaen_US
dc.contributor.authorStansby, Gerarden_US
dc.contributor.authorBottasso, Oscaren_US
dc.contributor.authorBahr, George M.en_US
dc.contributor.authorGrange, Johnen_US
dc.date.accessioned2020-12-23T08:59:13Z-
dc.date.available2020-12-23T08:59:13Z-
dc.date.issued2009-
dc.identifier.urihttps://scholarhub.balamand.edu.lb/handle/uob/1758-
dc.description.abstractThe mycobacteria are one of a number of genera making up the aerobic Actinomycetales. Their antigens demonstrable by immuno-precipitation methods can be divided into four groups. The group i antigens, common to all mycobacterial species, cross-react with their counterparts in animal cells, largely derived from mitochondria. Notable amongst these antigens are the heat-shock, or stress, proteins and possibly bacterial sugars. Tests of cell-mediated immunity show that people can be separated by their responsiveness in skin-test, or lymphocyte proliferation techniques, into four categories of responders. Category 1 individuals respond to all mycobacterial reagents through recognition of the group i antigens. Many chronic diseases are associated with a lack of cell-mediated responsiveness to the group i antigens, and have a raised antibody titre to them. This reflects a predominance of T helper 2 activity and reduced T helper 1 responsiveness as part of the pathogenesis of their diseases, which include chronic bacterial, viral and parasitic infections, allergies, autoimmunities and neoplasms. Packaged together, the group i antigens and the cell-wall adjuvants of selected aerobic Actinomycetales make potent immuno- modulatory reagents. An example is heat-killed Mycobacterium vaccae, useful in both prevention and treatment of disease. Treatment with such reagents results in alleviation of disease, restoration of cellular responsiveness to the common mycobacterial antigens and a decrease in antibody titres to them. This new approach to treatment for such a wide range of diseases has few disadvantageous side effects and can accompany other non-immunosuppressive therapies.en_US
dc.format.extent12 p.en_US
dc.language.isoengen_US
dc.subjectCommon antigensen_US
dc.subjectHeat shock/stress proteinsen_US
dc.subjectActinomycetalesen_US
dc.subjectMycobacterium vaccaeen_US
dc.subject.lcshImmunotherapyen_US
dc.titleThe common mycobacterial antigens and their importance in the treatment of diseaseen_US
dc.typeJournal Articleen_US
dc.contributor.affiliationFaculty of Medicineen_US
dc.description.volume15en_US
dc.description.issue11en_US
dc.description.startpage1248en_US
dc.description.endpage1260en_US
dc.date.catalogued2017-11-14-
dc.description.statusPublisheden_US
dc.identifier.OlibID174973-
dc.relation.ispartoftextJournal of current pharmaceutical designen_US
dc.provenance.recordsourceOliben_US
Appears in Collections:Faculty of Medicine
Show simple item record

Record view(s)

60
checked on Nov 21, 2024

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.